Skip to main content

Advertisement

SpringerLink
Log in

TNF-α Antagonists and Immunization

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Tumor necrosis factor (TNF) antagonists have proven to be very effective in the treatment of several autoimmune-mediated inflammatory diseases. The two classes of TNF antagonists—soluble TNF receptors and TNF monoclonal antibodies—have several important structural, pharmacokinetic, and functional differences. TNF antagonists interfere at different steps in the immune response to infections and vaccines. The immune response to pneumococcal polysaccharide vaccines is impaired in patients treated with methotrexate with some additional immunosuppressive effect of TNF antagonists. The secondary immune responses to inactivated and live attenuated vaccines, such as yellow fever vaccine, during treatment with TNF antagonists is mostly adequate despite significantly lower antibody levels. Little is known about the primary immune response to inactivated travel-related vaccines, but it is likely to be poor. Primary vaccination with live attenuated vaccines of patients receiving TNF antagonists should be avoided at all times.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745–56.

    Article  PubMed  CAS  Google Scholar 

  2. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9:271–85.

    Article  PubMed  CAS  Google Scholar 

  3. Murphy KM, Travers P, Walport M. Janeway’s immunobiology. 7th ed. November 2007 page 383

  4. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645–68.

    Article  PubMed  CAS  Google Scholar 

  5. Tracey D, Klareskog L, Sasso E, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–79.

    Article  PubMed  CAS  Google Scholar 

  6. Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol. 2010;161:1–9.

    PubMed  CAS  Google Scholar 

  7. •• Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8:601–11. This review elucidates why soluble TNFR and TNF monoclonal antibodies have a different effect on the granulomatous infections, such as tuberculosis.

    Article  PubMed  CAS  Google Scholar 

  8. Rigby WFC. Drug insight: different mechanisms of action of tumour necrosis factor antagonists—passive-aggressive behaviour? Nat Clin Pract Rheumatol. 2007;3:227–33.

    Article  PubMed  CAS  Google Scholar 

  9. Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998;102:322–8.

    Article  PubMed  CAS  Google Scholar 

  10. Roukens AH, Visser LG. Yellow fever vaccine: past, present and future. Expert Opin Biol Ther. 2008;8:1787–95.

    Article  PubMed  CAS  Google Scholar 

  11. Scheinberg M, Guedes-Barbosa LS, Mangueira C, et al. Yellow fever revaccination during infliximab therapy. Arthritis Care Res (Hoboken). 2010;62:896–88.

    Article  Google Scholar 

  12. Badsha H, Daher M, Edwards CJ. Live polio vaccine exposure while receiving anti-TNF therapy for reactive arthritis. Int J Rheum Dis. 2010;13:184–96.

    Article  PubMed  Google Scholar 

  13. Toussirot E, Wendling D. Bacillus calmette-guérin vaccination in a patient treated with infliximab. J Rheumatol. 2005;32:2500–1.

    PubMed  Google Scholar 

  14. Borte S, Liebert UG, Borte M, et al. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatol (Oxford). 2009;48:144–8.

    Article  CAS  Google Scholar 

  15. Elkayam O, Caspi D, Reitblatt T, et al. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2004;33(4):283–8.

    Article  PubMed  CAS  Google Scholar 

  16. Mease PJ, Ritchlin CT, Martin RW, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol. 2004;31:1356–61.

    PubMed  CAS  Google Scholar 

  17. Kapetanovic MC, Saxne T, Sjöholm A, et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatol (Oxford). 2006;45:106–11.

    Article  CAS  Google Scholar 

  18. Kaine JL, Kivitz AJ, Birbara C, et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007;34:272–9.

    PubMed  CAS  Google Scholar 

  19. Visvanathan S, Keenan GF, Baker DG, et al. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol. 2007;34:952–7.

    PubMed  CAS  Google Scholar 

  20. Gelinck LBS, van der Bijl AE, Visser LG, et al. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody response to the 23-valen pneumococcal polysaccharide vaccine. Vaccine. 2008;26:3528–33.

    Article  PubMed  CAS  Google Scholar 

  21. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis. 2006;65:191–4.

    Article  PubMed  CAS  Google Scholar 

  22. Kapetanovic MC, Saxne T, Nilsson JA, et al. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatol (Oxford). 2007;46:608–11.

    Article  CAS  Google Scholar 

  23. Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:851–6.

    Article  PubMed  Google Scholar 

  24. Gelinck LB, van der Bijl AE, Beyer WE, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 2008;67:713–176.

    Article  PubMed  CAS  Google Scholar 

  25. Elkayam O, Bashkin A, Mandelboim M, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2010;39:442–7.

    Article  PubMed  CAS  Google Scholar 

  26. Salemi S, Picchianti-Diamanti A, Germano V, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin Immunol. 2010;134:113–20.

    Article  PubMed  CAS  Google Scholar 

  27. Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine. 2010;28:5109–13.

    Article  PubMed  CAS  Google Scholar 

  28. •• Rahier JF, Moutschen M, Van Gompel A, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatol (Oxford). 2010;49:1815–27. This article provides a very practical review on recurrent issues of vaccination in patients with autoimmune inflammatory disease.

    Article  CAS  Google Scholar 

  29. • van Assen S, Elkayam O, Agmon-Levin N, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European league against rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev. 2010 Dec 20. [Epub ahead of print]. This article is a very comprehensive systematic review on infection risks and efficacy of vaccination in patients with rheumatic disease.

Download references

Disclosure

Conflicts of interest: L.G. Visser—service on speakers’ bureaus, Crucell and Sanofi.

Author information

Authors and Affiliations

  1. Infectious Disease Specialist, Department of Infectious Diseases, Leiden University Medical Centre, C5P-41, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands

    Leo G. Visser

Authors
  1. Leo G. Visser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leo G. Visser.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Visser, L.G. TNF-α Antagonists and Immunization. Curr Infect Dis Rep 13, 243–247 (2011). https://doi.org/10.1007/s11908-011-0183-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-011-0183-y

Keywords

Search

Navigation